FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial

Quoin Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug ...

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.
Medscape

Expanded Pediatric Indication for Topical Roflumilast Under FDA Review

Roflumilast 0.05% (Zoryve), a topical phosphodiesterase-4 inhibitor, is currently approved for treating mild-to-moderate AD in children aged 2 years or older; it was approved for ...
Health.com

11 Ways To Relieve an Itchy Sunburn Fast

Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...